BlackRock’s Aardvark Therapeutics AARD Stock Holding History

BlackRock’s Portfolio AARD Stock Details AARD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.99M	Buy	792,571 +8,141	+1%	+$84.4K	﹤0.01%	4016
2025 Q4	$10.3M	Buy	784,430 +474,965	+153%	+$5.93M	﹤0.01%	3455
2025 Q3	$4.11M	Buy	309,465 +103,670	+50%	+$1.17M	﹤0.01%	3852
2025 Q2	$2.78M	Buy	205,795 +187,019	+996%	+$1.93M	﹤0.01%	3967
2025 Q1	$141K	Buy	+18,776	New	+$211K	﹤0.01%	4679

Other funds holding AARD

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock's AARD Position: Q1 2026 in Review

BlackRock increased its Aardvark Therapeutics (AARD) stake by 1% in Q1 2026, buying an estimated $84.4K and bringing the position to 792,571 shares worth $2.99M. The position accounts for ﹤0.01% of the portfolio, ranked #4016.

BlackRock first reported a position in AARD in Q1 2025 and has held it in 5 quarters since. The position peaked at $10.3M in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

BlackRock held 792,571 shares of Aardvark Therapeutics worth $2.99M as of Q1 2026.
BlackRock bought 8,141 Aardvark Therapeutics shares in Q1 2026, an estimated $84.4K.
Aardvark Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4016 holding.
BlackRock first reported a position in Aardvark Therapeutics in Q1 2025 and has held it in 5 quarters since.
BlackRock's Aardvark Therapeutics position peaked at $10.3M in Q4 2025.
79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.